Created by potrace 1.10, written by Peter Selinger 2001-2011

In Silico Toxicology

Learn how our AI powered toxicity prediction platform can help to secure project funding and support early-stage decision making.

Created by potrace 1.10, written by Peter Selinger 2001-2011

In vitro Toxicology

Discover how our human-centric in vitro toxicology platforms enhance translational relevance and enable high-throughput screening for targeted toxicity assessments.

In Vivo Toxicology

Explore our comprehensive in vivo toxicology studies using physiologically relevant test systems. Our services support robust safety evaluations across all stages of drug development.

News feed

Stay up to date with our latest announcements, research breakthroughs, and company updates.

Accreditation list

ITR has been FDA, SCC and EMA inspected and is AAALAC and CCAC accredited.

About

ITR Laboratories

ITR Laboratories is a leading nonclinical contract research organization (CRO) providing GLP-compliant safety and toxicology testing services to pharmaceutical and biotechnology companies worldwide. With over 35 years of experience and a purpose-built facility in Montreal, we deliver high-quality, regulatory-compliant studies across general toxicology, safety pharmacology, genetic and immunotoxicology, inhalation, infusion, and more. Our personalized approach, scientific excellence, and proven track record of nearly 6,000 completed studies make ITR a trusted partner in bringing safe and effective therapies to market.

0+

Years in the industry

0+

Total studies completed

0+

Employees

0+

Immunology & Analytical Scientists

0+

Toxicologists

0+

Pathologists

Explore our

In Silico Toxicology Services

Everything you should know about our in Silico toxicology services

Explore our

In Vitro Toxicology Services

Everything you should know about our in Vitro toxicology services

Here are some of our

Partner Testimonies

ITR has been a service provider to L2 Consulting for many years. They have consistently proven to be reliable and diligent in on-time and on-budget deliverables. of particular note is the delivery of a projected executional Gantt chart with each study proposal that is extremely helpful in study scheduling and forward planning.

Leigh Berryman, L2 Consulting Inc.Partner

We engaged with ITR to perform a range of IND-enabling toxicology and safety studies for our new class of antibiotic, RECCE®327. Their long experience with this type of work and the quality of their study directors have provided an important bank of data for our drug development.

Michele Dilizia, Recce PharmaceuticalsExecutive Director & CSO

ITR is one of the best inhalation facilities in the world. I have conducted many studies there and they are always highly technically proficient, closely attuned to sponsor needs, and provide innovative approaches when needed. I highly recommend them.

Ronald Wolff, RK Wolff Safety Consulting IncPresident

I’ve been working with ITR Laboratories for 14 years, and they’ve consistently exceeded my expectations. Their responsiveness is outstanding, and their services are top quality. The team is professional, reliable, and always goes above and beyond. Highly recommend them to anyone looking for a preclinical lab that deliver great results!

Maxime Ranger, PhD MBA, Neurenati TherapeuticsCEO

ITR was an exceptional partner throughout our inhalation studies. From protocol development to study completion, the collaboration was seamless and highly professional. Our Study Director, Rommel, demonstrated outstanding attention to detail, and every member of the ITR team we worked with contributed to a truly positive experience.

James L. Ellis, Ph.D., Nocion TherapeuticsCSO

After collaborating for almost 20 years, I can say that ITR Laboratories is an excellent partner for biotech start-ups navigating preclinical and IND-enabling programs. Their team is highly collaborative, and they understand the realities of tight timelines and limited resources. ITR Laboratories delivers high-quality data while remaining flexible and pragmatic—exactly what early-stage companies need.

Karl-Rudolf Erlemann, KreamedicaPresident & CEO